GLP-1 analogs have been investigated as a potential option of pharmacotherapy for the management of psychiatric disorders since obesity and diabetes have been considered as independent risk factors for mental illness since they may play significant role in pathogenesis of psychiatric disorders [26], e.g., patients with T2DM are twice as likely to develop depression in comparison to healthy population [27]. The gene discussed is GLP1R; the disease is obesity disorder.